Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 26, 2010

Genentech Acquires Preclinical Human IL-17 mAb from NovImmune

  • Genentech has acquired exclusive rights to a fully human IL-17 mAb from NovImmune, along with access to back-up antibodies. NovImmune claims the late preclinical-stage antibody could have applications as a therapeutic candidate against multiple autoimmune diseases. As part of the deal the firm will receive an up-front payment from Genentech in addition to clinical milestones and future sales royalties.

    NovImmune is dedicated to discovering and developing therapeutic mAbs for the treatment of immune-related disorders. The company’s pipeline includes candidates against type 1 diabetes, Crohn disease, transplantation-related conditions, and autoimmune/inflammatory diseases. Lead candidate NI-0401 is a fully human anti-CD3 mAb designed to bind and modulate the CD3 epsilon chain expressed on T cells. The product is currently in mid-late-stage trials for the treatment of type 1 diabetes, Crohn disease, and transplantation indications.

    A Phase II-stage anti-inflammatory mAb candidate NI-0801 is designed to bind specifically and selectively to the human chemokine IP-10 (CXCL10) and inhibit the interaction of IP-10 with its cognate receptor and glycosaminoglycans.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »